Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The AAPS Journal|July 25, 2009
Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimatesSudhakar M Pai, Suzette Girgis, Vijay K Batra, et al.
The AAPS Journal|December 16, 2005
Pharmacodynamic parameter estimation: population size versus number of samplesSuzette Girgis, Sudhakar M Pai, Ihab G Girgis, et al.
Expert Opinion on Investigational Drugs|April 21, 2020
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participantsShalabh Singhal, Ihab G Girgis, Jenny Xie, et al.
Clinical and Translational Science|November 3, 2022
First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2Ian M Catlett, Urvi Aras, Lars Hansen, et al.
British Journal of Clinical Pharmacology|March 22, 2020
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participantsIan M Catlett, Miroslawa Nowak, Sudeep Kundu, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
Dermatology and Therapy|November 19, 2023
Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese SubjectsShan Jing, Yang Lin, Randy Dockens, et al.
Epilepsia|October 1, 2010
Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of ageIhab G Girgis, Partha Nandy, Jeffrey S Nye, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Shalabh Singhal, Raymond Darbenzio, et al.
Dermatology and Therapy|September 2, 2021
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 InhibitorsAnjaneya Chimalakonda, James Burke, Lihong Cheng, et al.
Pageof 2